Get the Stockscreener App
10.80
17.97%
1.645
After Hours:
11.35
0.55
+5.09%
Cervomed Inc stock is traded at $10.80, with a volume of 344.10K.
It is up +17.97% in the last 24 hours and down -19.88% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$9.155
Open:
$9.27
24h Volume:
344.10K
Relative Volume:
3.58
Market Cap:
$89.14M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.1321
EPS:
-9.54
Net Cash Flow:
$-7.45M
1W Performance:
+12.50%
1M Performance:
-19.88%
6M Performance:
-45.37%
1Y Performance:
+8.76%
1-Day Range:
$9.16
$11.50
1-Week Range:
$7.75
$11.50
52-Week Range:
$5.85
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
10.80 | 89.14M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
Cervomed Inc Stock (CRVO) Latest News
FDA grants Orphan Drug status to CervoMed's dementia drug By Investing.com - Investing.com South Africa
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug - Pharmaceutical Technology
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled - MSN
CervoMed's (CRVO) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
CervoMed stock gains on FDA orphan tag (CRVO:NASDAQ) - Seeking Alpha
CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod - Marketscreener.com
CervoMed announces ODD granted to neflamapimod by U.S. FDA - TipRanks
FDA grants Orphan Drug status to CervoMed's dementia drug - Investing.com
CervoMed Announces Orphan Drug Designation Granted to - GlobeNewswire
CervoMed's Dementia Drug Neflamapimod Secures FDA Orphan Drug Status | CRVO Stock News - StockTitan
CervoMed Reports Promising Results in Phase 2b Trial for Dementia Treatment - Citybuzz
CRVO (CervoMed) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
CRVO (CervoMed) EPS without NRI : $-1.65 (TTM As of Sep. 2024) - GuruFocus.com
Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment - Benzinga
CRVO (CervoMed) Debt-to-EBITDA : 0.00 (As of Sep. 2024) - GuruFocus.com
CervoMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CRVO (CervoMed) EV-to-Revenue : (As of Nov. 20, 2024) - GuruFocus.com
CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St
CervoMed shares coverage initiated with buy rating on DLB drug potential - Investing.com
CervoMed initiated with a Buy at D. Boral Capital - TipRanks
D. Boral Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed Inc. (NASDAQ:CRVO) Sees Large Growth in Short Interest - MarketBeat
CervoMed FY2024 EPS Lowered by Brookline Capital Management - MarketBeat
AWM Investment Company, Inc. Expands Stake in CervoMed Inc - GuruFocus.com
CervoMed Inc. (CRVO) Quarterly 10-Q Report - Quartzy
CervoMed appoints Ordonez, Rosch as SVPs - TipRanks
CervoMed bolsters leadership for neurologic drug development By Investing.com - Investing.com Nigeria
CervoMed bolsters leadership for neurologic drug development - Investing.com
CervoMed Announces Key Senior Leadership Appointments - GlobeNewswire
CervoMed Bolsters Leadership Team Ahead of Crucial Lewy Body Dementia Drug Trial | CRVO Stock News - StockTitan
CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials - TipRanks
CervoMed Inc. Announces Executive Appointments - Marketscreener.com
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed's Q3 Loss Widens to $4.8M Despite $46.7M Cash Reserve; Awaits Key Trial Data | CRVO Stock News - StockTitan
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences - StockTitan
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed Announces Key Takeaways from Oral Presentations at - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 7.6% in October - MarketBeat
CervoMed (NASDAQ:CRVO) Shares Down 3.1% – Time to Sell? - Defense World
CervoMed (NASDAQ:CRVO) Stock Price Down 3.1%What's Next? - MarketBeat
CervoMed to Present Phase 2b Trial Results - TipRanks
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Insiders of CervoMed Inc. (NASDAQ:CRVO) were rewarded after last week’s 11% gain - Simply Wall St
CRVOCervoMed Inc. Latest Stock News & Market Updates - StockTitan
CervoMed Announces Last Patient Last Visit in Phase 2b - GlobeNewswire
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - StockTitan
CervoMed Ends $20 Million Stock Sales Agreement with BTIG - Yahoo Finance
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):